These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2472924)

  • 1. Activation-dependent epitopes in the terminal complement pathway.
    Mollnes TE; Lea T; Tschopp J
    Complement Inflamm; 1989; 6(3):223-35. PubMed ID: 2472924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The killer molecule of complement.
    Müller-Eberhard HJ
    J Invest Dermatol; 1985 Jul; 85(1 Suppl):47s-52s. PubMed ID: 3891882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An enzyme-linked immunoabsorbent assay for the quantitation of the terminal complement complex from cell membranes or in activated human sera.
    Gawryl MS; Simon MT; Eatman JL; Lint TF
    J Immunol Methods; 1986 Dec; 95(2):217-25. PubMed ID: 3794343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.
    Würzner R; Schulze M; Happe L; Franzke A; Bieber FA; Oppermann M; Götze O
    Complement Inflamm; 1991; 8(5-6):328-40. PubMed ID: 1724954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.
    Mollnes TE; Lea T; Frøland SS; Harboe M
    Scand J Immunol; 1985 Aug; 22(2):197-202. PubMed ID: 2412280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunoenzyme determination of the C5b-9 complex of the complement system].
    Rus H; Niculescu F; Cristea A; Vlaicu R
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1986; 31(1):35-40. PubMed ID: 3738363
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantitation of activation of the human terminal complement pathway by ELISA.
    Sanders ME; Schmetz MA; Hammer CH; Frank MM; Joiner KA
    J Immunol Methods; 1985 Dec; 85(2):245-56. PubMed ID: 2416846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephritis.
    Kawana S; Shen GH; Kobayashi Y; Nishiyama S
    Arch Dermatol Res; 1990; 282(3):183-7. PubMed ID: 2369144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly.
    Podack ER; Tschoop J; Müller-Eberhard HJ
    J Exp Med; 1982 Jul; 156(1):268-82. PubMed ID: 6177822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
    Hetland G; Bungum L
    APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a human C5 beta-chain epitope exposed in the native complement component but concealed in the SC5b-9 complex.
    Mollnes TE; Klos A; Tschopp J
    Scand J Immunol; 1988 Sep; 28(3):307-12. PubMed ID: 2461581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
    Stewart JL; Kolb WP; Sodetz JM
    J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human alveolar macrophages synthesize the functional alternative pathway of complement and active C5 and C9 in vitro.
    Hetland G; Johnson E; Aasebø U
    Scand J Immunol; 1986 Nov; 24(5):603-8. PubMed ID: 3787189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The terminal complement complex in sera deficient in the eighth component of complement (C8).
    Mollnes TE; Lea T; Rogde S; Tedesco F
    Scand J Immunol; 1986 Sep; 24(3):307-12. PubMed ID: 3749815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor.
    Tschopp J; Mollnes TE
    Proc Natl Acad Sci U S A; 1986 Jun; 83(12):4223-7. PubMed ID: 2424021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9.
    Mollnes TE; Tschopp J
    J Immunol Methods; 1987 Jun; 100(1-2):215-21. PubMed ID: 2439601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice.
    Fu X; Ju J; Lin Z; Xiao W; Li X; Zhuang B; Zhang T; Ma X; Li X; Ma C; Su W; Wang Y; Qin X; Liang S
    Sci Rep; 2016 Jul; 6():30239. PubMed ID: 27444648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amastigotes of Trypanosoma cruzi escape destruction by the terminal complement components.
    Iida K; Whitlow MB; Nussenzweig V
    J Exp Med; 1989 Mar; 169(3):881-91. PubMed ID: 2494292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using polymerized C9 to produce a monoclonal antibody against a neoantigen of the human terminal complement complex.
    Kusunoki Y; Takekoshi Y; Nagasawa S
    J Pharmacobiodyn; 1990 Jul; 13(7):454-60. PubMed ID: 2290128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
    Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
    Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.